Back    Zoom +    Zoom -
翰森製藥(03692.HK)創新藥昕越第三項適應症獲藥品註冊證書
Recommend
1
Positive
0
Negative
0
aacat by AASTOCKS
Open a new trading account to get TENCENT shares!
翰森製藥(03692.HK)公布，創新藥昕越®(伊奈利珠單抗注射液)獲中國國家藥品監督管理局簽發藥品註冊證書，批准增加適應症：本品與常規治療藥物聯合用於治療抗乙酰膽鹼受體或抗肌肉特異性酪氨酸激酶抗體陽性的成人全身型重症肌無力患者。此為昕越獲批的第三項適應症。(de/d)

Switch to Auto-Translated Version
AASTOCKS新聞
  • Remark
  • (1) HK Indices are real time
Home|RT Quote|Market|News|Indices
Feedback|Disclaimer
View: Mobile|Desktop
Lang: 繁|简|EN
Back To Top
Contact Us
Email: support@aastocks.com